Observational studyBMC cardiovascular disorders2025
MR-proANP, sST2, BNP and sinus rhythm maintenance 1 year after electrical cardioversion for atrial fibrillation.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03351816 (Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe assessed the ability of MR-proANP, sST2 and BNP to predict maintenance of sinus rhythm at one year after successful electrical cardioversion of atrial fibrillation.
methodsProspective, multicenter, observational study including patients undergoing electrical cardioversion of persistent AF. MR-proANP, sST2 and BNP were measured in peripheral venous blood before cardioversion. Primary endpoint was the first recurrence of AF during the 12-month follow-up, defined as ECG showing AF, or any AF episode lasting > 30 s on 24 h holter monitoring.
resultsWe included 61 patients from 12/2017 to 03/2019 with preserved LVEF (≥ 45%), average age was 67.4 ± 7.8 years, 46 were males (75.4%). Sinus rhythm was restored in 51 patients (83.6%). In these 51 patients, plasma concentrations of MR-proANP were significantly higher among patients with recurrent AF at 12 months than among those without recurrence (314.45 [210.90-342.50] vs 214.50 [138.97-264.72] pmol/L, p < 0.01). There was no difference between groups in terms of sST2 and BNP concentrations. ROC curve analysis identified an MR-proANP threshold of 311.5 pmol/L as having the best predictive value for recurrent AF at 12 months. By multivariable analysis, MR-proANP > 311.5 pmol/L was found to be the sole predictor of AF recurrence (hazard ratio, 4.74; 95% CI, 1.59-14.07), and identified subjects at very high risk of recurrence (positive predictive value = 83.3%).
conclusionElevated MR-proANP level independently predicts recurrent AF during the year following electrical cardioversion of atrial fibrillation. Our findings warrant confirmation in larger studies.
trial registrationRegistered with ClinicalTrials.gov under the identifier NCT03351816 on 2017-11-20.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.